Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes
<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...
Main Authors: | Lotta, LA, Stewart, ID, Sharp, SJ, Day, FR, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, LBL, Kerrison, ND, Khaw, K-T, McCarthy, MI, O'Rahilly, S, Scott, RA, Savage, DB, Perry, JRB, Langenberg, C, Wareham, NJ |
---|---|
Format: | Journal article |
Published: |
American Medical Association
2018
|
Similar Items
-
Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes
by: Lotta, L, et al.
Published: (2018) -
Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis
by: Lotta, L, et al.
Published: (2016) -
Peningkatan rasio Low Density Lipoprotein Cholesterol dengan High Density Lipoprotein Cholesterol sebagai faktor resiko stroke iskemik
by: , ARITYAWAN, Fred Septo, et al.
Published: (2007) -
Genome-wide association study of adipocyte lipolysis in the GENetics of adipocyte lipolysis (GENiAL) cohort
by: Kulyté, A, et al.
Published: (2020) -
In vitro and in vivo lipolysis of plasma triglycerides increases the resistance to oxidative modification of low-density lipoproteins.
by: Skoglund-Andersson, C, et al.
Published: (2003)